(+/-)-2-amino-3-methoxy-2-methylpropan-1-ol | 96388-72-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (+/-)-2-amino-3-methoxy-2-methylpropan-1-ol
• 英文别名: 2-Amino-3-methoxy-2-methylpropan-1-ol
• CAS: 96388-72-6
• 化学式: C₅H₁₃NO₂
• mdl: MFCD16788617
• 分子量: 119.164
• InChiKey: XMBFYOWTPIQTEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-2-amino-3-methoxy-2-methylpropan-1-ol 生成 3-Methoxy-2-((6-chrysenylmethyl)amino)-2-methyl-1-propanol
  参考文献：
  名称：

  BAIR, KENNETH W.

  摘要：

  DOI：
• 作为产物：
  描述：

  4-aza-3-methoxymethyl-3-methyl-1-oxaspiro[4.5]decane 生成 (+/-)-2-amino-3-methoxy-2-methylpropan-1-ol
  参考文献：
  名称：

  BAIR, KENNETH W.

  摘要：

  DOI：

文献信息

• [(1-Pyrenylmethyl)amino] alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies
  作者：Kenneth W. Bair、Richard L. Tuttle、Vincent C. Knick、Michael Cory、David D. McKee

  DOI：10.1021/jm00171a012

  日期：1990.9

  additional basic amine groups in the side chain enhances DNA binding due to electrostatic interactions. Those compounds containing only a single basic benzylic amine bind similarly to DNA. Only the presence of bulky side chains appears to decrease the DNA interactions in the compounds examined. Although antitumor activity is seen for (1-pyrenylmethyl)amino alcohols, useful antitumor activity in the series

  在这项工作中研究的一系列1-吡啶基甲胺中，研究了结构，与DNA的相互作用以及鼠类抗肿瘤活性之间的关系。结合研究表明，所有这些1-pyrenylmethylamine衍生物都通过嵌入在一定程度上与DNA结合。由于静电相互作用，侧链中额外碱性胺基的存在增强了DNA的结合。那些仅包含单一碱性苄基胺的化合物与DNA的结合类似。仅存在庞大的侧链似乎会减少所检测化合物中的DNA相互作用。尽管对于（1-苯甲基甲基）氨基醇具有抗肿瘤活性，但是该系列中有用的抗肿瘤活性限于带有2-氨基-1，3-丙二醇型侧链的同类物。这些衍生物与DNA适度结合。DNA结合是该系列抗肿瘤活性的必要但不充分的标准。另外，在活性化合物组中，DNA结合的强度与抗肿瘤活性不相关。三种相关的2-[（（芳基甲基）氨基] -1,3-丙二醇衍生物（AMAPs）[crisnatol（770U82），773U82和502U83]目前正在作为潜在的抗肿瘤药物进行临床试验。
• [EN] SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1 (2H)-ONE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1(2H)-ONES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：ASTRAZENECA AB

  公开号：WO2016162325A1

  公开（公告）日：2016-10-13

  Compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 have any of the meanings defined hereinbefore in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer are disclosed.

  公式（I）的化合物或其药用盐，其中R1、R2、R3、R4、R5和R6具有在描述中定义的任意含义，揭示了它们的制备方法、含有它们的药物组合物以及它们在癌症治疗中的用途。
• A general synthesis of novel acyclic chiral α-tertiary amines
  作者：Renaud Beaudegnies、Clemens Lamberth

  DOI：10.1016/j.tetlet.2020.152463

  日期：2020.10

  A surprisingly high number of tert-butylamine derivatives, in which two of its three methyl groups have been replaced by cyano, ethynyl, methoxyiminomethyl, methoxymethyl, methylsulfanylmethyl and vinyl, have never been described in the literature. We have developed two general synthesis routes towards such acyclic chiral primary amines, in which the amino function is linked to an asymmetrically substituted

  在文献中从未描述过惊人数量的叔丁基胺衍生物，其中其三个甲基中的两个已被氰基，乙炔基，甲氧基亚氨基甲基，甲氧基甲基，甲基硫烷基甲基和乙烯基取代。我们已经针对这种无环手性伯胺开发了两条通用的合成路线，其中氨基官能团连接到一个不对称取代的季碳原子上。本文详细描述了九种先前未知的α-取代的O-甲基丙氨醇和α-甲基取代的炔丙基胺的制备。
• Phenanthro[2,3-6]thiophene derivatives, pharmaceutical compositions and
  申请人：Burroughs Wellcome Co.

  公开号：US04910218A1

  公开（公告）日：1990-03-20

  The present invention relates to anti tumor compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteroatom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（式（I）的化合物包括这些醚，总碳原子数不超过29）的抗肿瘤化合物；它们的醚，酯；酸加成盐；其中Ar是由5元环和6元环组成的融合四环芳香环系统，并含有至少一个杂原子和3个芳香环，总环原子数不超过18，或其取代衍生物；杂原子最好是氧、硫或氮；当它是氮时，被氢、甲基或乙基取代；R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-5烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10为氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14为氢、甲基、羟基或羟甲基。
• Phenanthrene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719055A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (1) ArCH.sub.2 R.sup.1 (1) or a monomethyl ether thereof (the compound of formula (1) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a phenanthrene or substituted phenanthrene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（1）ArCH.sub.2 R.sup.1（1）或其单甲醚（公式（1）的化合物包括这些醚，其总碳原子数不超过30）; 它们的醚，酯; 酸加成盐; 其中Ar是菲或取代菲环系统; R.sup.1包含不超过八个碳原子，是一个组##STR1##其中m为0或1; R.sup.5为氢; R.sup.6和R.sup.7相同或不同，每个为氢或C.sub.1-3烷基，可选地被羟基取代; R.sup.8和R.sup.9相同或不同，每个为氢或C.sub.1-3烷基;##STR2##是一个五元或六元饱和碳环; R.sup.10为氢，甲基或羟甲基; R.sup.11，R.sup.12和R.sup.13相同或不同，每个为氢或甲基; R.sup.14为氢，甲基，羟基或羟甲基。